Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Major Shareholder Sells $183,726.00 in Stock

Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPIGet Rating) major shareholder Global Strategic Fund I. Venbio sold 17,700 shares of Checkmate Pharmaceuticals stock in a transaction dated Wednesday, May 11th. The shares were sold at an average price of $10.38, for a total transaction of $183,726.00. Following the sale, the insider now owns 2,412,105 shares in the company, valued at $25,037,649.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of NASDAQ CMPI opened at $10.43 on Friday. Checkmate Pharmaceuticals, Inc. has a 1-year low of $2.00 and a 1-year high of $10.48. The company has a 50-day moving average of $5.55 and a two-hundred day moving average of $4.01.

Checkmate Pharmaceuticals (NASDAQ:CMPIGet Rating) last announced its earnings results on Tuesday, March 29th. The company reported ($0.62) earnings per share for the quarter. On average, equities research analysts anticipate that Checkmate Pharmaceuticals, Inc. will post -3.14 earnings per share for the current year.

Several brokerages have recently weighed in on CMPI. Zacks Investment Research upgraded shares of Checkmate Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, May 3rd. BTIG Research downgraded shares of Checkmate Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, April 20th.

Several hedge funds and other institutional investors have recently made changes to their positions in CMPI. Millennium Management LLC acquired a new stake in shares of Checkmate Pharmaceuticals during the 4th quarter worth approximately $31,000. BlackRock Inc. grew its position in shares of Checkmate Pharmaceuticals by 126.7% during the 3rd quarter. BlackRock Inc. now owns 51,794 shares of the company’s stock worth $205,000 after buying an additional 28,944 shares during the period. Finally, Decheng Capital Management III Cayman LLC acquired a new stake in shares of Checkmate Pharmaceuticals during the 1st quarter worth approximately $4,253,000. 74.56% of the stock is owned by institutional investors.

About Checkmate Pharmaceuticals (Get Rating)

Checkmate Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma.

Featured Stories

Insider Buying and Selling by Quarter for Checkmate Pharmaceuticals (NASDAQ:CMPI)

Receive News & Ratings for Checkmate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkmate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.